Swedish Orphan Biovitrum Ab (Publ)
SpainAll drugs from this manufacturer
-
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia B, a disorder caused by the deficiency or dysfunction of factor IX.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eftrenonacog alfa 1000 UI -
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia B, a hereditary disorder caused by the deficiency or dysfunction of factor IX.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eftrenonacog alfa 2000 UI -
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia B, a disorder caused by the deficiency or dysfunction of factor IX.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eftrenonacog alfa 250 UI -
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia B, a disorder caused by the deficiency or malfunction of factor IX.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eftrenonacog alfa 3000 UI -
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia B, a hereditary disorder caused by the deficiency or dysfunction of factor IX.
Dosage form: powder and solvent for solution for injection
Active substance Dosage eftrenonacog alfa 500 UI -
It is used to treat and prevent bleeding episodes in people with hemophilia A, a hereditary disorder caused by a deficiency or malfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efanesoctocog alfa 1000 UI -
It is used to treat and prevent bleeding episodes in people with hemophilia A, a hereditary disorder caused by a deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efanesoctocog alfa 2000 UI -
It is used to treat and prevent bleeding episodes in patients with hemophilia A, a hereditary disorder caused by a deficiency or malfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efanesoctocog alfa 250 UI -
It is used to treat and prevent bleeding episodes in patients with hemophilia A, a hereditary disorder caused by the deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efanesoctocog alfa 3000 UI -
It is used to treat and prevent bleeding episodes in patients with hemophilia A, a hereditary disorder caused by a deficiency or malfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efanesoctocog alfa 4000 UI -
It is used to treat and prevent bleeding episodes in patients with hemophilia A, a hereditary disorder caused by a deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efanesoctocog alfa 500 UI -
It is used to treat adults with paroxysmal nocturnal hemoglobinuria (PNH) who present with anemia due to this disease. It is also used in adults and adolescents (aged 12 to 17 years) with C3 glomerulopathy (C3G) or primary immune complex-mediated membranoproliferative glomerulonephritis (primary IC-MPGN), generally in conjunction with a renin-angiotensin system inhibitor.
Dosage form: solution for infusion
Active substance Dosage pegcetacoplan 54 mg -
It is used in adults with chronic liver disease to treat low platelet levels before a medical procedure with a risk of bleeding. It is also used to treat adults with low platelet levels due to chronic immune thrombocytopenia (ITP) when other treatments have not worked.
Dosage form: tablets, film-coated
Active substance Dosage avatrombopag maleate 23.6 mg -
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by the deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 133,3 µg -
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 200 µg -
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 266,7 µg -
It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 33,3 µg -
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by a deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 400 µg -
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by the deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 4000 UI -
It is used to treat and prevent bleeding in patients of all ages with hemophilia A, a hereditary disorder caused by a deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 66,7 µg -
It is used to treat and prevent bleeding in patients of any age with hemophilia A, a disorder caused by the deficiency or dysfunction of factor VIII.
Dosage form: powder and solvent for solution for injection
Active substance Dosage efmoroctocog alfa 750 UI -
It is used to treat rheumatoid arthritis in adults, COVID-19 in patients with pneumonia who require oxygen and are at risk of pulmonary failure, Still's disease, familial Mediterranean fever, and various periodic fever syndromes (CAPS, NOMID/CINCA, Muckle-Wells, and familial cold autoinflammatory syndrome).
Dosage form: solution for injection
Active substance Dosage anakinra 150 mg